Literature DB >> 17394868

[Value of resting and exercise mitral regurgitation during exercise echocardiography to predict outcome in patients with left ventricular dysfunction].

Jesús Peteiro1, Lorenzo Monserrat, Pablo Piñón, Alberto Bouzas, Rosa Campos, Ignacio Mosquera, Javier Mariñas, Beatriz Bouzas, Alfonso Castro-Beiras.   

Abstract

INTRODUCTION AND
OBJECTIVES: The relative value of exercise echocardiography (EE) over resting echocardiography when this last incorporates information on mitral regurgitation (MR) is unknown. Furthermore, limited data exists regarding to the value of MR worsening during exercise in patients with LV dysfunction. We investigated whether: a) EE has incremental value over a resting echo-Doppler study; and b) post-exercise MR increments the value of EE for predicting outcome in patients with LV dysfunction.
METHODS: 388 consecutive patients with LV dysfunction (LV ejection fraction <50%) were followed for 2.1 (1.5) years. There were 46 hard events (myocardial infarction in 10 and cardiac death in 36).
RESULTS: There were 43 events in 319 patients with abnormal EE vs 3 events in 69 patients with normal EE (13% vs 4%, P=.04), whereas there were 20 events in the 103 patients with at least moderate resting MR vs 26 events in the 288 with no/mild MR (19% vs 9%, P=.006). Resting MR, peak heart rate x blood pressure, and n masculine of diseased territories on EE were independently associated to hard events. The same variables and MR worsening were independently associated to cardiac death.
CONCLUSIONS: EE maintains its higher prognostic value over resting echocardiography even when this last incorporates information on MR. MR worsening increments the value of EE for predicting cardiac death in patients with LV dysfunction.

Entities:  

Mesh:

Year:  2007        PMID: 17394868

Source DB:  PubMed          Journal:  Rev Esp Cardiol        ISSN: 0300-8932            Impact factor:   4.753


  1 in total

1.  Exercise echocardiography.

Authors:  Jesus Peteiro; Alberto Bouzas-Mosquera
Journal:  World J Cardiol       Date:  2010-08-26
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.